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824FO-5 Matrix Remodeling in Human Aortic Valve Disease 
Olivier Fondard, Delphine Detaint. Homa Adle, Bernard lung, Jean-Paul Couetil, Ulrich 
Hvass, Mohamed Jarraya, Jean Gerota. Dominique Henin, Alec Vahanian, Jean-Baptiste 
Michel, Marie-Paule Jacob, CHU Xavier Bichat. Paris, France 
Background: Aortic valve diseases are characterized by pathological remodeling of val- 
vular tissue but the cellular and molecular effecters involved in these processes are not 
well known. Here, we investigated the role of matrix metalloproteinases (MMPs) MMP-2, 
MMP-9, MMP-3, MMP-7 and their inhibitors TlMPs (TIMP-1 and TIMP-2) in human aortic 
valve disease. 
Methods: Pathological valves were collected during surgery. and the controls, non-cryo- 
preserved homografts, were obtained from a human tissue bank. Valves were classified 
according to their pathology and divided into 3 groups : aortic stenosis (AS) (n=49), aortic 
regurgitation (AR) (n=24), aortic controls (n=4). Valves were studied histologically at the 
cellular and extracellular matrix levels. The biochemical analyses (gelatin and casein 
zymography, reverse zymography, ELISA and Western blot) were performed on valve 
extracts. 
Results: Histological study showed fibrotic, inflammatory and calcified lesions in AS, and 
disorganization of collagen bundles and elastic fibers in AR. MMP-9 activity was signifi- 
cantlv increased in AS compared to AR (AS : 20915 f 2865 : AR : 7776 * 1786 densito- 
metric units/pg of proteins i p=O.OOl). MMP-3 activity was significantly increased in AS 
cornoared to controls and AR IAS : 9469 r 1196 : AR : 5611 r 1611 : controls : 290 * 290 
den&metric units/vg of proteins ; p<O.O5). T&l was significantly increased in AS 
compared to controls and AR (AS : 51 * 3 ; AR : 34 f 4 ; controls : 11 * 3 ngllO0 pg of 
proteins ; p<O.OOl). The MMP-S/TIMP-1 ratio was significantly decreased in AS and AR 
compared to controls (AS : 415 + 55 ; AR : 426 * 215 ; controls : 2523 f 1295 ; 
pcO.0001). Results obtained for MMP-2, MMPJ and TIMP-2 were not statistically differ- 
ent between groups. 
Conclusion: This study demonstrates the involvement of the MMP system in the extracel- 
lular matrix remodeling of both AS and AR. The increases in MMP-9 and MMP-3 clearly 
provide further proof of the inflammatory state of the pathological valves. These changes 
are more severe in AS than in AR. 
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624FO-6 Percutaneous Implantation of Prosthetic Heart Valves: 
From Animal Model to First Human Implantation in 
Calcific Aortic Stenosis 
Alain Cribler, Helene Eltchamnoff, Chrlstophe Tron, Fabrtce Bauer, Genevieve 
Derumeaux, Assaf Bash, Nicolas Borenstein, Charles Nicolle Hospital, Rouen. France 
Background: Percutaneous implantation of prosthetic heart valve (PHV) was shown to 
be feasible in animal and in human for pulmonary valve replacement. We developed a 
new PHV made of three bovine pericardial leaflets mounted into a stainless steel balloon- 
expandable stent (Percutaneous Valve Technologies, USA). This PHV was first tested in 
animals before being implanted as the last resolt procedure in a 57 y-old patient with cal- 
cific amtic stenosis in cardiogenic shock, with severe associated diseases, for whom SUP 
gery had been declined. 
Methods: In animals, PHV was implanted in 51 sheep at various sites: descending aorta 
(n=12), native pulmonaiy valve (PV: n=24) or aortic valve (A&: n=l5). PHV was crimped 
on a 23 mm diameter expandable balloon, introduced through a 24 F sheath via the jug- 
ular vein or the carotid attely. and pushed over an extrastiff wire. PHV function was 
assessed by hemodynamics. angiography. PD-and trans-esophageal echocardiography 
(TEE) and Doppler. For human implantation, the same technique was applied. The per- 
cutaneous antegrade trans-septal route via the right femoral vein was used due to severe 
peripheral artery disease (PAD). Post-procedure PHV function was assessed by left ven- 
tricle and suora-aortic anaioorams and bv TEE everv 2 weeks durina follow-up. 
Results: In animals, a&rate PHV delivery was obtained in all buth cases. ‘Successful 
imolantations led to satisfactorv PHV function. Complications were earlv death I< 3h) in 6 _ 
AoV and 2 PV cases and acute (AoV: 2, PV: 3) or delayed (AoV : 2; PV; 2) PHV migra- 
tion. PHV function remained normal in 21126 sheep (AoV: 2, PV : 19) with chronic (> 2 
week) follow-up. In the patient case, PHV was accurately positioned within the native 
valve. PHV function was excellent: gradient 5 mmHg (from 30 mmHg), valve area 1.7 
cm2 (from 0.6 cm2), with mild paraprothetic aortic regurgitation and no coronary occlu- 
sion, and remained optimal during follow-up, leading to hemodynamic and clinical 
improvement. The patient died of non cardiac cause (complication of right leg amputation 
for gangrene) 4 month after PHV implantation. 
Conclusions: PHV might become an important therapeutic option in selected non-oper- 
able patients with calcific amtic stenosis. 
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1134-21 Natriuretic Peptide Plasma Levels Remain Elevated Six 
Months After Aortic Valve Replacement for Severe 
Aortic Stenosis 
lvor L. Getier, Ralph A. Stewart, Malcolm E. Legget, Teena M. West, Renelle French, 
John K. French, Timothy G. Yandle, A. Mark Richards, Harvey D. White, Green Lane 
Hospital, Auckland, New Zealand, Cardicendocrine Research Group, Christchurch, New 
Zealand 
Introduction: Plasma natriuretic peptide (NP) levels are increased in amtic stenosis 
(AS) and correlate with dtsease severity, but the effects of aoltic valve replacement 
(AVR)on NPs are unknown. 
Methods: Twenty-three patients with AS, mean age 72*12 years, mean aortic valve 
area 0.74+0.19 cm2 underwent echocardiography and measurement of brain natriuretic 
peptide (BNP), atrial natriuretic peptide (ANP) and N-terminal brain natriuretic peptide 
(N-BNP) within 24 hours pre AVR and 6 months post AVR. A tissue valve was used in 18 
patients and a mechanical valve in 5 patients. Combined AVR and coronary artery 
bypass graft surgery was performed in 11 patients. Plasma levels of BNP, ANP and N- 
BNP were measured in 23 age and gender matched controls. 
Results: BNP, ANP and N-BNP were higher in AS patients pre AVR compared with con- 
trols, PcO.0001 for all, and remained elevated 6 months post AVR (Table). Mean * SD 
echo measures pre AVR and 6 months post AVR were: peak aortic velocity 4.6+0.7 vs 
2.3i0.3 m/s, P < 0.0001, mean aortic gradient 51i16 vs 12*3 mmHg. P<O.OOOl, LV 
mass 226*59 vs 200+56 g, P=O.O5, and LV fractional shortening 35+12 vs. 35+8%, 
P=O.82 respectively. There were no regional wall motion abnormalities 6 months post 
AVR. 
Conclusion: Despite reductions in aortic gradients and LV mass, NP levels remain ele- 
vated 6 months post AVR. This suggests the process of remodeling of the left ventricle is 
incomplete. 
Control Pre AVR 6 Months 
“fP SP 
BNP 7 (5-9) 25 (9-35) 16 (10.25) 0.08 <0.0001 
•N- NP 17 (11-32) 96 (42-l 55) 75 (44-l 10) 0.04 <0.0001 
ANP 12 (9.14) 32 (21-43) 30 (22-37) 0.64 <0.0001 
NP levels expressed as median (interquartile range) pmolil t6 months post AVR vs 
pre AVR; 
$ 6 months post AVR vs. control 
1134-22 N-Terminal Pro-SNP as a Biochemical Marker for 
Assessing Severity of Aortic Stenosis 
Michael W. Weber, Matthias Rau, Christian Malkowski. Eva Keil, Vesselin Mitrovic, 
Ruzika Maksimovic, Roland R. ??randt, Christian Hamm, Kerckhoff Heart Centre, Bad 
Nauheim. Germany 
Background: NT-proBNP a neurohormon is secreted from the myccardium and has 
shown to be a sensitive and specific marker for ventricular wall stress. Aortic stenosis 
(AS) leads to pressure overload of the left ventricle and thus to increased wall stress. Aim 
of this study was to evaluate the use of NT-proBNP for grading of aoltic stenosis. 
Methods: 68 consecutive patients (36 male; aged 70+9,4) with aortic stenosis and 17 
patients (11 male; aged 70+7,8) after (> 6 month) aortic valve replacement (AVR) were 
included. In all patients NT-proBNP plasma levels were measured (Elecsys, Roche diag- 
nostics). Transaortic pressure gradient (PG mean) and aortic valve area (AVA) were 
assessed by transthoracic and transesophageal echocardiography. 
Results: Mean pressure gradient ranged from 10 to 117 mm Hg (mean 43 mm Hg) and 
AVA (n = 31) from 0,45 to 1 ,ll cm2 (mean 0.77 cm’). NT-proBNP levels correlated to the 
degree of aoltic stenosis (p < 0.01). There was a significant correlation of NT-proBNP to 
the mean transaortic gradient and to leftventricular mass (Rho 0,474; Rho 0.338; p -z 
0,Ol). AVA was inversly correlated ( Rho = - 0,48; p < 0,Ol). 
